Dangshe Ma
Overview
Explore the profile of Dangshe Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al.
Proc Natl Acad Sci U S A
. 2014 Jan;
111(5):1766-71.
PMID: 24443552
Using an expanded genetic code, antibodies with site-specifically incorporated nonnative amino acids were produced in stable cell lines derived from a CHO cell line with titers over 1 g/L. Using...
12.
Haddish-Berhane N, Shah D, Ma D, Leal M, Gerber H, Sapra P, et al.
J Pharmacokinet Pharmacodyn
. 2013 Aug;
40(5):557-71.
PMID: 23933716
Objectives of the present investigation were: (1) to compare three literature reported tumor growth inhibition (TGI) pharmacodynamic (PD) models and propose an optimal new model that best describes the xenograft...
13.
Marozsan A, Ma D, Nagashima K, Kennedy B, Kang Y, Arrigale R, et al.
J Infect Dis
. 2012 Jun;
206(5):706-13.
PMID: 22732923
The spore-forming bacterium Clostridium difficile represents the principal cause of hospital-acquired diarrhea and pseudomembranous colitis worldwide. C. difficile infection (CDI) is mediated by 2 bacterial toxins, A and B; neutralizing...
14.
Wang X, Ma D, Olson W, Heston W
Mol Cancer Ther
. 2011 Jul;
10(9):1728-39.
PMID: 21750220
Prostate-specific membrane antigen (PSMA) is a membrane protein that is overexpressed manifold in prostate cancer and provides an attractive target for therapy. PSMA ADC is an antibody-drug conjugate (ADC) that...
15.
Ma D, Hopf C, Malewicz A, Donovan G, Senter P, Goeckeler W, et al.
Clin Cancer Res
. 2006 Apr;
12(8):2591-6.
PMID: 16638870
Prostate-specific membrane antigen (PSMA) is the prototypic cell-surface marker of prostate cancer and provides an attractive target for monoclonal antibody (mAb) targeted therapies. In this study, a novel antibody-drug conjugate...
16.
Milenic D, Garmestani K, Brady E, Albert P, Ma D, Abdulla A, et al.
Cancer Biother Radiopharm
. 2005 Oct;
20(5):557-68.
PMID: 16248771
These studies demonstrate the feasibility of targeted therapy for the treatment of disseminated peritoneal disease using (212)Pb-labeled Herceptin as an in vivo generator of (212)Bi. In vitro studies compare the...
17.
Milenic D, Garmestani K, Brady E, Albert P, Ma D, Abdulla A, et al.
Clin Cancer Res
. 2004 Dec;
10(23):7834-41.
PMID: 15585615
The studies reported herein demonstrate the efficacy of alpha-particle-targeted radiation therapy of peritoneal disease with Herceptin as the targeting vehicle. Using the CHX-A-DTPA linker, Herceptin was radiolabeled with indium-111 and...
18.
Schulke N, Varlamova O, Donovan G, Ma D, Gardner J, Morrissey D, et al.
Proc Natl Acad Sci U S A
. 2003 Oct;
100(22):12590-5.
PMID: 14583590
Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane glycoprotein that serves as an attractive target for cancer immunotherapy by virtue of its abundant and restricted expression on the...
19.
McDevitt M, Ma D, Simon J, Frank R, Scheinberg D
Appl Radiat Isot
. 2002 Oct;
57(6):841-7.
PMID: 12406626
The alpha-particle-emitting radionuclides 213Bi, 211At, 224Ra are under investigation for the treatment of leukemias, gliomas, and ankylosing spondylitis, respectively. 213Bi and 211At were attached to monoclonal antibodies and used as...
20.
Jurcic J, Larson S, Sgouros G, McDevitt M, Finn R, Divgi C, et al.
Blood
. 2002 Aug;
100(4):1233-9.
PMID: 12149203
Unlike beta particle-emitting isotopes, alpha emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has...